The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Indications/Uses
Rybrevant as monotherapy is indicated for treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based therapy.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign Out
